Canopy Growth Q2 revenue misses estimates as Europe sales hit by supply chain issues

Canopy Growth

07/11/2025 12:09

Overview

Canopy Growth Q2 FY2026 revenue grows 6% yr/yr, missing analyst expectations

Adjusted EBITDA loss improves to C$3 mln in Q2 FY2026

Canada adult-use cannabis revenue up 30% in Q2 FY2026

Outlook

Company expects Canada adult-use cannabis growth in H2 FY2026

Company anticipates improved European supply chain by FY2026 end

Storz & Bickel revenue growth expected in Q3 FY2026

Result Drivers

CANADA ADULT-USE GROWTH - Revenue up 30% driven by growth in infused pre-roll joints and new vapes from Tweed and 7ACRES

MEDICAL CANNABIS GROWTH - Revenue up 17% due to more insured patients and larger order sizes

INTERNATIONAL CHALLENGES - Revenue down 39% due to supply chain issues in Europe

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
C$67 mln
C$70.88 mln (4 Analysts)
Q2 Adjusted EBITDA
-C$3 mln
Q2 Gross Margin
33.00%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Canopy Growth Corp is C$2.00, about 22.5% above its November 6 closing price of C$1.55

Press Release: ID:nBw7Dpsrza

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)